Cardiac Arrest, Out-Of-HospitalNCT05376267
Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)
A study testing Therapeutic Hypothermia in people with Cardiac Arrest, Out-Of-Hospital and Hypothermia, Induced, run by University of Michigan at 65 sites in 5 countries.
Trial summary
This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest. Read more about this study
- Who is it for?
- Ages 2 days to 17 years
- Conditions the study is for
- Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
- What is being tested?
- Therapeutic Hypothermia
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 900 participants
- Where
- 65 sitesin 5 countries
- Study dates
- 5 Aug 2022to 31 Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 days to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Age 2 days to < 18 years with corrected gestational age of at least 38 weeks
- Chest compressions for at least 2 minutes
- Coma or encephalopathy after resuscitation from Out-of-Hospital Cardiac Arrest (OHCA)
- Requires continuous mechanical ventilation through endotracheal tube or tracheostomy
- Definitive temperature control device initiated
- Randomization within 6 hours of Return of Spontaneous Circulation (ROSC)
- Informed consent from Legally Authorized Representative (LAR) including intent to maintain life support for 120 hours
Who cannot join
- Glasgow Coma Motor Score (GCMS) = 6
- LAR does not speak English or Spanish
- Duration of Cardiopulmonary Resuscitation (CPR) > 60 minutes
- Severe hemodynamic instability with continuous infusion of epinephrine or norepinephrine of 2 micrograms per kilogram per minute (μg/kg/minute) or initiation of Extracorporeal membrane oxygenation (ECMO)
- Pre-existing severe neurodevelopmental deficits with Pediatric Cerebral Performance Category (PCPC) =5 or progressive degenerative encephalopathy
- Pre-existing terminal illness, unlikely to survive to one year
Show all 19Show fewer
- Cardiac arrest associated with brain, thoracic, or abdominal trauma
- Active and refractory severe bleeding prior to randomization
- Extensive burns or skin lesions incompatible with surface cooling
- Planned early withdrawal of life support before 120 hours
- Sickle cell anemia
- Pre-existing cryoglobulinemia
- Non-fatal drowning in ice covered water
- Central nervous system tumor with ongoing chemotherapy
- Previous enrollment in P-ICECAP trial
- Prisoner
- Chronic hypothermia
- New post-cardiac arrest diabetes insipidus
- Pregnancy
Trial locations and contacts
65 sites in 5 countries. Contact the study team or a site near you to ask about taking part.
65 sites in 5 countries
United States52 sites, 49 recruiting
- Recruiting
Children's Hospital Medical Center of Akron
Akron, Ohio, 44308
Ryan Nofziger, MD, 330-543-8639, mofziger@akronchildrens.org
Chris Page-Goertz, MD, 330-543-8639, cpage-goertz@akronchildrens.org
- Recruiting
Albany Medical Center
Albany, New York, 12208
Ilana Harwayne-Gidansky, MD, 5182625127, harwayi@amc.edu
Ilana Harwayne-Gidansky, MD
- Recruiting
University of Michigan CS Mott Children's Hospital
Ann Arbor, Michigan, 48109
Ryan Barbaro, MD, barbaror@umich.edu
Ryan Barbaro, MD
- Recruiting
University of Maryland Children's Hospital
Baltimore, Maryland, 21201
Siddhartha Dante, MD, abhutta@som.umaryland.edu
Siddhartha Dante, MD
- Recruiting
Johns Hopkins Medicine Children's Center
Baltimore, Maryland, 21287
Caitlin O'Brien, MD, MPH, 720-635-1730, Cobrie19@jhmi.edu
Caitlin O'Brien, MD, MPH
- Recruiting
University of Alabama at Birmingham / Children's of Alabama
Birmingham, Alabama, 35233
Michele Kong, MD, 205-638-9387, mkong@uabmc.edu
Michele Kong, MD
- Recruiting
MassGeneral Hospital for Children
Boston, Massachusetts, 02114
Sarah MD Murphy, MD, 617-724-4380, samurphy@mgh.harvard.edu
Sarah Murphy, MD
- Recruiting
University of Buffalo / Oishei Children's Hospital
Buffalo, New York, 14203
Ryan Breuer, MD, ryanbrue@buffalo.edu
Ryan Breuer, MD
- Recruiting
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599-7220
Kieran Leong, DO, 919-966-7495, Kieran_Leong@med.unc.edu
Benny Joyner, MD, MPH
- Recruiting
Ann & Robert Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
Craig Smith, MD, 312-227-4800, CMSmith@luriechildrens.org
Craig Smith, MD
- Recruiting
Comer Children's Hospital, University of Chicago
Chicago, Illinois, 60637
Casey Stulce, MD, 7738343837, cstulce@bsd.uchicago.edu
Casey Stulce, MD
- Recruiting
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229
Ranjit Chima, MD, ranjit.chima@cchmc.org
Ranjit Chima, MD
- Recruiting
Ohio State University / Nationwide Children's Hospital
Columbus, Ohio, 43205
Marlina Lovett, MD, marlina.lovett@nationwidechildrens.org
Marlina Lovett, MD
- Recruiting
Medical City Children's Hospital
Dallas, Texas, 75230
G. Kris Bysani, M.D. MS, FAAP, FCCM, 972 566 8340, kbysani@pacant.com
G. Kris Bysani, M.D. MS, FAAP, FCCM
- Recruiting
Children's Medical Center of Dallas
Dallas, Texas, 75235
Joshua Wolovits, MD, joshua.wolovits@utsouthwestern.edu
Joshua Wolovits, MD
- Recruiting
Dayton Children's Hospital
Dayton, Ohio, 45404
Hemanth Lingadevaru, MD, 9376415168, lingadevaruh@childrensdayton.org
Hemanth Lingadevaru, MD
- Recruiting
Children's Hospital of Michigan
Detroit, Michigan, 48201
Kathleen Meert, MD, 313-745-5870, meert1kl@cmich.edu
Kathleen Meert, MD
- Recruiting
University of Florida (UF) Health Shands Children's Hospital
Gainesville, Florida, 32610-0296
Shruthi Mahadevaiah, MD, 313-318-7383, smahadevaiah@ufl.edu
Shruthi Mahadevaiah, MD
- Recruiting
Penn State University / Penn State Children's Hospital
Hershey, Pennsylvania, 17033
Neal Thomas, MD, nthomas@pennstatehealth.psu.edu
Neal Thomas, MD
- Recruiting
Children's Memorial Hermann Hospital
Houston, Texas, 77030
Thao Nguyen, MD, 832 512 1595, Thao.L.Nguyen@uth.tmc.edu
- Recruiting
Texas Children's Hospital, Baylor
Houston, Texas, 77030
Jennifer Erklauer, MD, jclee@bcm.edu
Jennifer Erklauer, MD
- Recruiting
Riley Children's Health
Indianapolis, Indiana, 46202
Matthew Yuknis, MD, 317-944-3345, myuknis@iupui.edu
Matthew Yuknis, MD
- Recruiting
University of Iowa, Carver College of Medicine
Iowa City, Iowa, 52242
Kari Wellnitz, MD, kari-wellnitz@uiowa.edu
Kari Wellnitz, MD
- Recruiting
Memorial Health - Miller Children's and Women's Hospital of Long Beach
Long Beach, California, 90806-1701
Christopher Babbitt, MD, 562-933-8743, CBabbitt@memorialcare.org
Christopher Babbitt, MD
- Recruiting
Children's Hospital of Los Angeles
Los Angeles, California, 90027
Bradley De Souza, MD, 323-361-8202, bdesouza@chla.usc.edu
David Baron, MS, 323-361-6329, dbaron@chla.usc.edu
- Recruiting
University of California Los Angeles (UCLA) Mattel Children's Hospital
Los Angeles, California, 90095
Anil Sapru, MD, asapru@mednet.ucla.edu
Anil Sapru, MD
- Recruiting
American Family Children's Hospital
Madison, Wisconsin, 53705
Peter Ferrazzano, MD, (608) 265-4839, ferrazzano@pediatrics.wisc.edu
Peter Ferrazzano, MD
- Recruiting
University of Tennesses Health Center / Le Bonheur Children's
Memphis, Tennessee, 38104
Laurel Metzler, MD, lmetzler@uthsc.edu
Laruel Metzler, MD
- Recruiting
University of Miami
Miami, Florida, 33124
Jennifer Munoz Pareja, MD, jcm457@med.miami.edu
Jennifer Munoz Pareja, MD
- Recruiting
Children's Wisconsin
Milwaukee, Wisconsin, 53226
Binod Balakrishnan, MD, 414-266-3360, bbalakris@mcw.edu
Binod Balakrishnan, MD
- Withdrawn
University of Minnesota Fairview Masonic Children's Hospital
Minneapolis, Minnesota, 55454
- Recruiting
J.W. Ruby Memorial Hospital
Morgantown, West Virginia, 26506
Ryan A Nofziger, MD, MBA, 304-293-1217, Ryan.Nofziger@hsc.wvu.edu
Ryan A Nofziger, MD, MBA
- Recruiting
Cohen Children's Medical Center of NY / Northwell Health
New Hyde Park, New York, 11040
Taylor Nickerson, MD, (718) 470-3668, tnickerson@northwell.edu
Todd Sweberg, MD
- Recruiting
Mount Sinai Icahn / Kravis Children's Hospital
New York, New York, 10029
Shubhi Kaushik, MD
Shubhi Kaushik, MD
- Recruiting
University of California - Oakland / UCSF Benoiff Children's Hospital Oakland
Oakland, California, 94609
Natalie Cvijanovich, MD, (510) 428-3302
Natalie Cvijanovich, MD
- Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, 68114
Alyson Baker, MD MS, 402-955-7257, alybaker@childrensnebraska.org
Alyson Baker, MD MS
- Recruiting
Children's Hospital of Orange County
Orange, California, 92868-4203
Adam Schwarz, MD, 714-509-8620, aschwarz@choc.org
Adam Schwarz, MD
- Recruiting
Children's Hospital of Illinois
Peoria, Illinois, 61637
Sandeep Tripathi, MD, 309-624-0719, sandeept@uic.edu
Sandeep Tripathi, MD
- Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
Matthew Kirschen, MD, kirschenm@chop.edu
Matthew Kirschen, MD
- Recruiting
Phoenix Children's Hospital
Phoenix, Arizona, 85016
F. Anthony Willyerd, MD, 602-471-5064, fwillyerd@phoenixchildrens.com
F. Anthony Willyerd, MD
- Recruiting
Children's Hospital of Pittsburgh (UPMC)
Pittsburgh, Pennsylvania, 15224
Ericka Fink, MD, finkel@ccm.upmc.edu
Ericka Fink, MD
- Recruiting
Oregon Health & Science University Doernbecher Children's Hospital
Portland, Oregon, 97239
Mohamud Daya, MD, MS, 503-494-7248, dayam@ohsu.edu
Serena Kelly, MS, 503-789-4580, phromsiv@ohsu.edu
- Recruiting
University of Rochester Medical Center
Rochester, New York, 14642-8667
Jake Deines, MD, 585-273-5269, Jake_deines@urmc.rochester.edu
Jake Deines, MD
- Recruiting
University of California, Davis
Sacramento, California, 95817
Heather Siefkes, MD, 916-734-7620, hsiefkes@ucdavis.edu
Heather Siefkes, MD
- Withdrawn
Primary Children's Hospital, University of Utah School of Medicine
Salt Lake City, Utah, 84108
- Recruiting
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229
Theodore Wu, MD, 210-567-5816, wut@uthscsa.edu
Theodore Wu, MD
- Recruiting
University of California - San Francisco (UCSF) Benioff Children's Hospital San Francisco
San Francisco, California, 94158
Patrick McQuillen, MD, patrick.mcquillen@ucsf.edu
Patrick McQuillen, MD
- Recruiting
Stanford
Santa Clara, California, 95050
Tim Cornell, MD, tcornell@stanford.edu
Tim Cornell, MD
- Recruiting
Washington University / St. Louis Children's Hospital
St Louis, Missouri, 63110
Stuart Friess, MD, friess@wustl.edu
Stuart Friess, MD
- Recruiting
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, 33701
Anthony Sochet, MD., M.Sc., 727-767-4343, asochet1@jh.edu
Nathan Dean, MD
- Recruiting
Montefiore Einstein Hospital Moses Campus
The Bronx, New York, 10467
Alvaro J Coronado Munoz, MD, 7187412432, acoronadom@montefiore.org
- Completed
Banner University Medical Center - Tucson
Tucson, Arizona, 85719
Australia7 sites, 7 recruiting
- Recruiting
Queensland Children's Hospital
Brisbane, Queensland, 4101
Adrian Mattke, MD, PhD, FRACP, FCICM, +61 (4) 0169 8994, Adrian.Mattke@health.qld.gov.au
Tara Williams, MSN, Tara.Williams@health.qld.gov.au
- Recruiting
Monash Medical Centre
Clayton, Victoria, 3168
Meredith Allen, MB.BS, FRACP, meredith.allen@monashhealth.org
Meredith Allen, MB.BS, FRACP
- Recruiting
Townsville University Hospital
Douglas, Queensland
Andrew Clift, FCICM, FACRRM, GMC, Andrew.Clift@health.qld.gov.au
Andrew Clift, FCICM, FACRRM, GMC
- Recruiting
Perth Children's Hospital
Nedlands, Western Australia
Simon Erikson, FRACP, 61 (8) 6456 4437, simon.erickson@health.wa.gov.au
Jenipher Chumbres Flores, MSN, Jenipher.ChumbesFlores@health.wa.gov.au
- Recruiting
Women's and Children's Hospital
North Adelaide, South Australia, 5006
Subdodh Ganu, MBBS, MD, FCICM, 61 8 8161 6881, subodh.ganu@sa.gov.au
Subdodh Ganu, MBBS, MD, FCICM
- Recruiting
Royal Children's Hospital
Parkville, Victoria, 3052
Warrick Butt, FELSO, FCICM, MBBS, 61 (4) 0777 6886, Warwick.Butt@rch.org.au
Warrick Butt, FELSO, FCICM, MBBS
- Recruiting
Gold Coast University Hospital
Southport, Queensland
Shane George, BSc MBBS MPH FACEM, +61 (4) 0169 8994, shane.george@uq.edu.au
Tara Williams, MSN, Tara.Williams@health.qld.gov.au
United Kingdom4 sites, 4 recruiting
- Recruiting
Birmingham Children's Hospital, United Kingdom
Birmingham
Hari Krishnan, MD, hari.krishnan2@nhs.net
Hari Krishnan, MD
- Recruiting
Bristol Royal Hospital for Children
Bristol, Bristol, BS2 8BJ
Omar Aziz, MSC, MRCGP, MRCPCH, DGM, 44 3788956254, Omer.Aziz@uhbw.nhs.uk
Omar Aziz, MSC, MRCGP, MRCPCH, DGM
- Recruiting
Leeds Children's Hospital
Leeds, LS1 3EX
Jo Lumsden, MBBCh, 44 113 392 8458 ext. 7447, jolumsden@nhs.net
Jo Lumsden, MBBCh
- Recruiting
Evelina London Children's Hospital
London, London, SE17EH
Andrew Nyman, MBBCh, 44 7825658012, Andrew.Nyman@gstt.nhs.uk
Andrew Nyman, MBBCh
Canada1 site, 1 recruiting
- Recruiting
The Hospital for Sick Children
Toronto, Ontario
Anne-Marie Guerguerian, MD, PhD, 416-813-7654, anne-marie.guerguerian@sickkids.ca
Anne-Marie Guerguerian, MD, PhD
New Zealand1 site, 1 recruiting
- Recruiting
Starship Children's Hospital
Grafton, Auckland, 1142
John S Beca, FRACP, FCICM, JohnBeca@adhb.govt.nz
John Beca, FRACP, FCICM
About this study
This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest.
The study team hypothesizes that longer durations of cooling may improve either the proportion of children that attain a good neurobehavioral recovery or may result in better recovery among the proportion already categorized as having a good outcome.
- Being tested
- Therapeutic Hypothermia
- Keywords
- Bayesian Adaptive Clinical Trial, Hypothermia, therapeutic, Coma, Pediatric
- Medical subject headings
- Out-of-Hospital Cardiac Arrest, Hypothermia, Hypoxia-Ischemia, Brain, Coma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Therapeutic HypothermiaDevice
Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming,
A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours.
| Study group | Role | What they receive |
|---|---|---|
| Cooling 0 hours | Experimental | Participants will be kept at a normal temperature for the whole 5 days. Receives: Device: Therapeutic Hypothermia |
| Cooling 12 hours | Experimental | The participant will be cooled to 33°Celsius (C) for 12 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. Receives: Device: Therapeutic Hypothermia |
| Cooling 18 hours | Experimental | The participant will be cooled to 33°C for 18 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. Receives: Device: Therapeutic Hypothermia |
| Cooling 24 hours | Experimental | The participant will be cooled to 33°C for 24 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. Receives: Device: Therapeutic Hypothermia |
| Cooling 36 hours | Experimental | The participant will be cooled to 33°C for 36 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. Receives: Device: Therapeutic Hypothermia |
| Cooling 48 hours | Experimental | The participant will be cooled to 33°C for 48 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. Receives: Device: Therapeutic Hypothermia |
| Cooling 60 hours | Experimental | The participant will be cooled to 33°C for 60 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. Receives: Device: Therapeutic Hypothermia |
| Cooling 72 hours | Experimental | The participant will be cooled to 33°C for 72 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. Receives: Device: Therapeutic Hypothermia |
| Cooling 84 hours | Experimental | The participant will be cooled to 33°C for 84 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. Receives: Device: Therapeutic Hypothermia |
| Cooling 96 hours | Experimental | The participant will be cooled to 33°C for 96 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. Receives: Device: Therapeutic Hypothermia |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vineland Adaptive Behavior Scales - Third Edition (VABS-3) Mortality Composite Score at 12 months after return of spontaneous circulation
The VABS-3 score, designed to be administered to surviving children with any level of function including comatose status to age-appropriate neurobehavioral functioning, ranges from 20 to 140 with age-corrected standardized mean and standard deviation of 100 and 15, respectively. Deaths will be scored as 0 in this trial.
Measured: 12 months after out-of-hospital cardiac arrest
Secondary outcomes (3)
Change in Pediatric Cerebral Performance Category (PCPC) at 12 months from baseline
The Pediatric Cerebral Performance Category is a global scale based on observer impressions. It's a six point graded scale of increasing disability from 1 normal function, to 6 death. Scores include 1 for good, 2 for mild disability, 3 for moderate disability, 4 for severe disability, and 5 for vegetative state or coma. Higher scores indicating worse performance or functional morbidity.
Measured: Baseline and 12 months after cardiac arrest
Pediatric Resuscitation after Cardiac Arrest (PRCA) at 12 months
The PRCA adapted from the Pediatric Stroke Outcome measure, ranges from 0-21 where lower scores indicate less impairment. Deaths will be assigned the worst score of 21 for PRCA.
Measured: 12 months after cardiac arrest
Survival at 12 months
Measured: 12 months after cardiac arrest
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 May 2022
- Study start5 Aug 2022
- Primary completion31 Mar 2028 (estimated)
- Study completion31 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac Arrest, Out-Of-HospitalStudies of the same condition, open and under way.
- More trials run by University of MichiganThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Bayesian Adaptive Design
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Michigan
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI), Kennedy Krieger Institute, Baltimore, MD
- Responsible party
- Principal investigator, Frank W. Moler, M.D, M.S, University of Michigan
- Investigators
- Frank Moler, MD, Principal investigator, University of MichiganAlex Topjian, MD, Principal investigator, Children's Hospital of PhiladelphiaWilliam Meurer, MD, Principal investigator, University of Michigan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05376267
- Sponsor's protocol ID
- IDE G210126
- Other IDs
- 1UG3HL159134-01, U24HL159132, HUM00206424
- Status last verified
- Oct 2026
- First submitted
- 11 May 2022
- Last updated
- 14 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: The data will be stored in the NHLBI data repository after trial completion.
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)
- ClinicalTrials.gov ID
- NCT05376267
- Acronym / sponsor ID
- IDE G210126
- Keywords
- Bayesian Adaptive Clinical Trial, Hypothermia, therapeutic, Coma, Pediatric
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 900 participants (estimated)
- Lead sponsor
- University of MichiganUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI), Kennedy Krieger Institute, Baltimore, MD
- Study start
- 5 Aug 2022 (actual)
- Primary completion
- 31 Mar 2028 (estimated)
- Study completion
- 31 Mar 2028 (estimated)
- First posted
- 17 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest.
The study team hypothesizes that longer durations of cooling may improve either the proportion of children that attain a good neurobehavioral recovery or may result in better recovery among the proportion already categorized as having a good outcome.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 10
- Model description
- Bayesian Adaptive Design
| Arm | Type | Receives |
|---|---|---|
| Cooling 0 hours | Experimental | Device: Therapeutic HypothermiaParticipants will be kept at a normal temperature for the whole 5 days. |
| Cooling 12 hours | Experimental | Device: Therapeutic HypothermiaThe participant will be cooled to 33°Celsius (C) for 12 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. |
| Cooling 18 hours | Experimental | Device: Therapeutic HypothermiaThe participant will be cooled to 33°C for 18 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. |
| Cooling 24 hours | Experimental | Device: Therapeutic HypothermiaThe participant will be cooled to 33°C for 24 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. |
| Cooling 36 hours | Experimental | Device: Therapeutic HypothermiaThe participant will be cooled to 33°C for 36 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. |
| Cooling 48 hours | Experimental | Device: Therapeutic HypothermiaThe participant will be cooled to 33°C for 48 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. |
| Cooling 60 hours | Experimental | Device: Therapeutic HypothermiaThe participant will be cooled to 33°C for 60 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. |
| Cooling 72 hours | Experimental | Device: Therapeutic HypothermiaThe participant will be cooled to 33°C for 72 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. |
| Cooling 84 hours | Experimental | Device: Therapeutic HypothermiaThe participant will be cooled to 33°C for 84 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. |
| Cooling 96 hours | Experimental | Device: Therapeutic HypothermiaThe participant will be cooled to 33°C for 96 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day. |
Who may qualify
- Ages
- 2 days to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (7 listed)
- Age 2 days to < 18 years with corrected gestational age of at least 38 weeks
- Chest compressions for at least 2 minutes
- Coma or encephalopathy after resuscitation from Out-of-Hospital Cardiac Arrest (OHCA)
- Requires continuous mechanical ventilation through endotracheal tube or tracheostomy
- Definitive temperature control device initiated
Key exclusion criteria (19 listed)
- Glasgow Coma Motor Score (GCMS) = 6
- LAR does not speak English or Spanish
- Duration of Cardiopulmonary Resuscitation (CPR) > 60 minutes
- Severe hemodynamic instability with continuous infusion of epinephrine or norepinephrine of 2 micrograms per kilogram per minute (μg/kg/minute) or initiation of Extracorporeal membrane oxygenation (ECMO)
- Pre-existing severe neurodevelopmental deficits with Pediatric Cerebral Performance Category (PCPC) =5 or progressive degenerative encephalopathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Therapeutic HypothermiaParticipants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours. | Device | Cooling 0 hours, Cooling 12 hours, Cooling 18 hours, Cooling 24 hours, Cooling 36 hours, Cooling 48 hours, Cooling 60 hours, Cooling 72 hours, Cooling 84 hours, Cooling 96 hours |
Primary outcome
Vineland Adaptive Behavior Scales - Third Edition (VABS-3) Mortality Composite Score at 12 months after return of spontaneous circulation
Time frame: 12 months after out-of-hospital cardiac arrest
The VABS-3 score, designed to be administered to surviving children with any level of function including comatose status to age-appropriate neurobehavioral functioning, ranges from 20 to 140 with age-corrected standardized mean and standard deviation of 100 and 15, respectively. Deaths will be scored as 0 in this trial.
3 secondary outcomes
Change in Pediatric Cerebral Performance Category (PCPC) at 12 months from baseline
Time frame: Baseline and 12 months after cardiac arrest
Pediatric Resuscitation after Cardiac Arrest (PRCA) at 12 months
Time frame: 12 months after cardiac arrest
Survival at 12 months
Time frame: 12 months after cardiac arrest
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2026.
- Individual participant dataSharing planned: Yes. The data will be stored in the NHLBI data repository after trial completion.
Related trials for Cardiac Arrest, Out-Of-Hospital
Not yet recruitingObservational study
CAROTID DOPPLER AND CEREBRAL OXIMERY IN POST CARDIAC ARREST ICU PATIENTS
Cardiac Arrest (CA), Carotid Doppler
Active, not recruitingPhase 3
The Danish Out-of-Hospital Cardiac Arrest Study
Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome
Not yet recruiting
Compression-Only Versus Standard Basic Life Support Training in Nursing Students
Cardiopulmonary Resuscitation, Out-of-Hospital Cardiac Arrest
Not yet recruiting
Execution of Prehospital Transesophageal Echocardiography During Cardiopulmonary Resuscitation in Patients With Out-of-hospital Cardiac Arrest
Out-of-hospital Cardiac Arrest (OHCA)
Active, not recruiting
The REVIVE-PEEP Trial: Positive End-expiratory Pressure Versus Sham Valve/Zero End-expiratory Pressure in Cardiopulmonary Resuscitation During Manual Ventilation to Improve Neurological Outcomes at Discharge in Adult Patients Suffering an Out-of-hospital Cardiac Arrest
Cardiac Arrest, Out-Of-Hospital
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Frank Moler, MD principal investigator
University of Michigan
Alex Topjian, MD principal investigator
Children's Hospital of Philadelphia
William Meurer, MD principal investigator
University of Michigan
65 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Therapeutic Hypothermia in people with Cardiac Arrest, Out-Of-Hospital and Hypothermia, Induced, run by University of Michigan at 65 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 65 sites in United States, Australia, United Kingdom, Canada, New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Frank Moler, MD (734-764-5302, fmoler@umich.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vineland Adaptive Behavior Scales - Third Edition (VABS-3) Mortality Composite Score at 12 months after return of spontaneous circulation (time frame: 12 months after out-of-hospital cardiac arrest). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2026.